However, due to concerns of macular atrophy or secondary choroidal neovascularization (CNV) development after PDT, and the potential for superimposed polypoidal neovasculopathy or secondary CNV in CSC patients, preference of anti-VEGF therapy as an initial treatment before PDT is increasing [34, 35]. This evidence concerns the gene VEGFA and choroidal neovascularization.